

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

VOLUNTARY ANNOUNCEMENT UPDATE ON AN INVESTIGATIONAL INHALED ANTIPSYCHOTIC PRODUCT

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 12 May 2020 and 13 July 2020 in relation to the pivotal Phase III trial of Staccato[®] loxapine for inhalation system (ADASUVE[®]) in China. The Board of the Company is pleased to announced that on 24 August 2020, Lee’s Pharmaceutical (HK) Limited (“**LPHK**”), a wholly-owned subsidiary of the Company, has successfully completed the analysis of unblinded topline data and the positive results thereof showed that this study has met its primary endpoint, a rapid onset of action was demonstrated by a statistically significant decrease ($p < 0.05$) from baseline in the Positive and Negative Syndrome Scale Excited Component (also known as PEC) score at 2 hours post dose. New Drug Application (“**NDA**”) is expected to be submitted by the end of 2020.

This pivotal Phase III multi-centre, randomised, double-blind, placebo-controlled, parallel group study (NCT04148963) is designed to evaluate the efficacy and safety of Staccato[®] loxapine or placebo in treating acute agitation in patients with schizophrenia or bipolar disorder (manic or mixed episodes) as defined by The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Patients may receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status. The primary endpoint is the change from baseline in the Positive and Negative Syndrome Scale Excited Component score, performed at 2 hours after the first dose.

* For identification purpose only

The study was conducted in 14 trial sites in China and 150 patients had been enrolled in total.

Individuals with bipolar disorder or schizophrenia are vulnerable to episodes of agitation, which can be defined as excessive verbal and motor behaviour, especially during exacerbations of their disease (Western Journal of Emergency Medicine 2016).

According to Journal of Affective Disorders 2017 and Journal of Global Health 2015, the pooled life time prevalence of bipolar I disorder in the general population of China was 0.09%, while the life time prevalence of schizophrenia was 0.83% in urban China.

ABOUT ADASUVE®

ADASUVE® is the first and only orally inhaled loxapine powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE® is a handheld, non-invasive and fast-acting alternative to currently used therapies. It was approved in 2012 by the U.S. Food and Drug Administration and in 2013 by European Medicines Agency. ADASUVE® was first commercially available in the U.S. in March 2014 and was licensed in by the Group from Alexza Pharmaceuticals, Inc. (“**Alexza**”) in October 2017 for China, Hong Kong SAR and Macau SAR.

ABOUT ALEXZA

Alexza Pharmaceuticals, Inc., Mountain View, California based company is focused on the research, development and commercialisation of novel, proprietary products for the acute treatment of underserved medical needs. Alexza is focused on finding new therapeutic solutions for conditions that would benefit from rapid, precise and non-invasive treatment. The Staccato® platform has the potential to address these needs and to provide flexibility to deliver the most important pharmaceutical benefits of therapeutics in an innovative way.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets 23 proprietary and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, ophthalmology, dermatology, obstetrics and urology. It has more than 60 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 3 September 2020

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.